Is BNTX or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to BNTX or SRRK?

In the previous week, BioNTech and BioNTech both had 8 articles in the media. Scholar Rock's average media sentiment score of 0.98 beat BioNTech's score of 0.86 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Scholar Rock N/A -163.52% -96.67%

Does the media prefer MRNA or SRRK?

In the previous week, Moderna had 40 more articles in the media than Scholar Rock. MarketBeat recorded 48 mentions for Moderna and 8 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.98 beat Moderna's score of 0.38 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 17 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to VTRS or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Viatris. Scholar Rock's average media sentiment score of 0.98 beat Viatris' score of 0.39 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GMAB or SRRK more profitable?

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Scholar Rock N/A -163.52% -96.67%

Does the media favor GMAB or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.06 beat Scholar Rock's score of 0.98 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRRK or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for BridgeBio Pharma and 8 mentions for Scholar Rock. BridgeBio Pharma's average media sentiment score of 1.30 beat Scholar Rock's score of 0.98 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Scholar Rock (SRRK) Competitors

$47.29 -0.01 (-0.02%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$47.30 +0.01 (+0.01%)

As of 07/31/2026 07:34 PM Eastern

Compare

SRRK vs. BNTX, MRNA, VTRS, GMAB, and BBIO

Should you buy Scholar Rock stock or one of its competitors? MarketBeat compares Scholar Rock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scholar Rock include BioNTech (BNTX), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO).

How does Scholar Rock compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioNTech and BioNTech both had 8 articles in the media. Scholar Rock's average media sentiment score of 0.98 beat BioNTech's score of 0.86 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus price target of $129.13, indicating a potential upside of 42.55%. Scholar Rock has a consensus price target of $56.21, indicating a potential upside of 18.87%. Given BioNTech's higher possible upside, research analysts clearly believe BioNTech is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.17	-$1.29B	-$5.88	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Scholar Rock	N/A	-163.52%	-96.67%

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Summary

Scholar Rock beats BioNTech on 8 of the 15 factors compared between the two stocks.

How does Scholar Rock compare to Moderna?

Moderna (NASDAQ:MRNA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Moderna had 40 more articles in the media than Scholar Rock. MarketBeat recorded 48 mentions for Moderna and 8 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.98 beat Moderna's score of 0.38 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	17 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than Moderna. Scholar Rock is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	9.84	-$2.82B	-$7.99	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Scholar Rock	N/A	-163.52%	-96.67%

Moderna presently has a consensus target price of $40.00, suggesting a potential downside of 27.03%. Scholar Rock has a consensus target price of $56.21, suggesting a potential upside of 18.87%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

75.3% of Moderna shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Scholar Rock beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Viatris?

Viatris (NASDAQ:VTRS) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Scholar Rock	N/A	-163.52%	-96.67%

Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.40	-$3.51B	-$0.26	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

79.9% of Viatris shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viatris presently has a consensus price target of $17.50, suggesting a potential downside of 0.34%. Scholar Rock has a consensus price target of $56.21, suggesting a potential upside of 18.87%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

In the previous week, Scholar Rock had 3 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Viatris. Scholar Rock's average media sentiment score of 0.98 beat Viatris' score of 0.39 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Scholar Rock	N/A	-163.52%	-96.67%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genmab A/S currently has a consensus target price of $39.28, suggesting a potential upside of 36.05%. Scholar Rock has a consensus target price of $56.21, suggesting a potential upside of 18.87%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

In the previous week, Scholar Rock had 3 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.06 beat Scholar Rock's score of 0.98 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.84	$963M	$1.32	21.87
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Genmab A/S has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Summary

Genmab A/S beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to BridgeBio Pharma?

Scholar Rock (NASDAQ:SRRK) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Scholar Rock has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
BridgeBio Pharma	$579.96M	27.00	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 2 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for BridgeBio Pharma and 8 mentions for Scholar Rock. BridgeBio Pharma's average media sentiment score of 1.30 beat Scholar Rock's score of 0.98 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock currently has a consensus target price of $56.21, suggesting a potential upside of 18.87%. BridgeBio Pharma has a consensus target price of $95.21, suggesting a potential upside of 18.88%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

BridgeBio Pharma beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.67B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-13.17	7.38	282.30	24.66
Price / Sales	N/A	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	19.62	16.96	10.98	6.07
Net Income	-$377.94M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.35%	-1.76%	-0.60%	-0.44%
1 Month Performance	-13.83%	-8.38%	-5.20%	-4.81%
1 Year Performance	30.06%	48.40%	62.01%	18.61%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	3.1329 of 5 stars	$47.29 0.0%	$56.21 +18.9%	+30.1%	$5.67B	N/A	N/A	140	Upcoming Earnings
BNTX BioNTech	4.0956 of 5 stars	$91.09 +2.0%	$129.13 +41.8%	-15.6%	$22.59B	$3.25B	N/A	7,807	Positive News Upcoming Earnings
MRNA Moderna	1.3467 of 5 stars	$55.63 +2.9%	$40.00 -28.1%	+98.6%	$21.45B	$2.20B	N/A	4,700	Trending News Earnings Report Options Volume Analyst Revision Gap Up
VTRS Viatris	2.2103 of 5 stars	$17.64 +2.3%	$17.50 -0.8%	+99.3%	$20.08B	$14.30B	N/A	30,000	Upcoming Earnings
GMAB Genmab A/S	4.6668 of 5 stars	$28.80 -0.2%	$39.28 +36.4%	+32.6%	$18.00B	$3.72B	21.82	3,029	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. BNTX, MRNA, VTRS, GMAB, and BBIO

How does Scholar Rock compare to BioNTech?

Summary

How does Scholar Rock compare to Moderna?

Summary

How does Scholar Rock compare to Viatris?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

How does Scholar Rock compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. BNTX, MRNA, VTRS, GMAB, and BBIO

How does Scholar Rock compare to BioNTech?

Do institutionals and insiders believe in BNTX or SRRK?

Does the media refer more to BNTX or SRRK?

Do analysts recommend BNTX or SRRK?

Which has preferable earnings & valuation, BNTX or SRRK?

Is BNTX or SRRK more profitable?

Which has more volatility & risk, BNTX or SRRK?

Summary

How does Scholar Rock compare to Moderna?

Does the media prefer MRNA or SRRK?

Which has more volatility & risk, MRNA or SRRK?

Which has higher earnings and valuation, MRNA or SRRK?

Is MRNA or SRRK more profitable?

Do analysts rate MRNA or SRRK?

Do institutionals & insiders hold more shares of MRNA or SRRK?

Summary

How does Scholar Rock compare to Viatris?

Is VTRS or SRRK more profitable?

Which has more risk & volatility, VTRS or SRRK?

Which has higher valuation & earnings, VTRS or SRRK?

Do institutionals and insiders have more ownership in VTRS or SRRK?

Do analysts prefer VTRS or SRRK?

Does the media refer more to VTRS or SRRK?

Summary

How does Scholar Rock compare to Genmab A/S?

Is GMAB or SRRK more profitable?

Do insiders & institutionals believe in GMAB or SRRK?

Do analysts recommend GMAB or SRRK?

Does the media favor GMAB or SRRK?

Which has better earnings and valuation, GMAB or SRRK?

Which has more risk & volatility, GMAB or SRRK?

Summary

How does Scholar Rock compare to BridgeBio Pharma?

Which has better earnings and valuation, SRRK or BBIO?

Does the media prefer SRRK or BBIO?

Do institutionals and insiders hold more shares of SRRK or BBIO?

Do analysts recommend SRRK or BBIO?

Which has more volatility and risk, SRRK or BBIO?

Is SRRK or BBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools